Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 84.8
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Steminent Biotherapeutics, Inc. develops novel cellular therapeutics and engages in the research and development of new stem cell drugs. Its products include stemchymal, stemchymal therapeutic advantages and stemchymal application fields. The company was founded on December 18, 2007 and is headquartered in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell